Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Doxorubicin (Adriamycin) is a Topoisomerase II (Top2) inhibitor with antineoplastic activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | Inquiry | Inquiry |
Description | Doxorubicin (Adriamycin) is a Topoisomerase II (Top2) inhibitor with antineoplastic activity. |
Targets&IC50 | Topoisomerase I:0.8 μM (IC50), Topoisomerase II:2.67 μM (IC50) |
In vitro | The combination of Doxorubicin and Simvastatin at the highest tested concentrations (2 μM and 10 μM, respec-tively) kills 97% of the Hela cells[2]. |
In vivo | Mice bearing PC3 xenografts are injected with 2, 4 or 8 mg/kg Doxorubicin and tumor volume is measured over time. A dose of 2 mg/kg does not affect tumor growth while higher dosages delay tumor growth initially (p<0.05 at days 18 and 22), 4 mg/kg or 8 mg/kg Doxorubicin significantly reduces levels of c-FLIP in PC3 xenografts[3]. In rats, a single intraperitoneal injection of 10 mg/kg (Doxorubicin 1), 10 daily intraperitoneal injections of 1 mg/kg (Doxorubicin 2), or in 5 weekly intraperitoneal injections of 2 mg/kg (Doxorubicin 3). An 80% mortality rate is observed at day 28 in Doxorubicin 1, while Doxorubicin 2 and Doxorubicin 3 reached 80% mortality on days 107 and 98, respectively. Fractional shortening decreased by 30% at week 2 in Doxorubicin DOX1, 55% at week 13 in Doxorubicin 2, and 42% at week 13 in Doxorubicin 3[4]. |
Cell Research | Doxorubicin is dissolved in stock solutions (1 mM) and serially diluted with RPMI 1640 media (0.1, 1, and 2 μM)[2]. 160 μL of Hela cells suspension (3×104 cell/mL) is dispensed into three 96-well U-bottom microplates and incubated for 24 h at 37°C in a fully humidified atmosphere of 5% CO2. In plate 1, serial dilutions of Doxorubicin (20 μL; final concentration, 0.1-2 μM) and Simvastatin (20 μL; final concentration, 0.25-2 μM) are added to a final volume of 200 μL and incubated for another 72 h. In plates 2 and 3 serial dilutions of each drug (Simvastatin or Doxorubicin, 40 μL) are added. After an incubation period of 24 h, the medium is aspirated and the cells are washed in PBS. Then, serial dilutions of other drug (40 μL) are added and supplemented with culture medium to a final volume of 200 μL, and incubated for 48 h. Doxorubicin and Simvastatin are used individually as positive controls (40 μL in each well), and the cells treated only with solvent are considered as negative controls. To evaluate cell survival, 20 μL of MTT solution (5 mg/mL in PBS) is added to each well and incubated for 3 h. Then the media is replaced with 150 μL of DMSO, and complete solubilization of formazan crystals is achieved by repeated pipetting of the solution. Absorbance is then determined at 540 nm by an ELISA plate reader. Each drug concentration is assayed in 4 or 8 wells and repeated 3 times. The cytotoxic/cytostatic effect of Doxorubicin is expressed as the relative viability (% control) and calculated. Percentage of cell survival in the negative control is assumed as 100. Relative viability=(experimental absorbance-background absorbance)/ (absorbance of untreated controls-background absorbance)×100 %[2]. |
Synonyms | Hydroxydaunorubicin, Adriamycin |
Molecular Weight | 543.52 |
Formula | C27H29NO11 |
CAS No. | 23214-92-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50mg/mL
DMSO: 10 mM
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Doxorubicin 23214-92-8 Chromatin/Epigenetic DNA Damage/DNA Repair PI3K/Akt/mTOR signaling AMPK Topoisomerase HIV Bacterial Hydroxydaunorubicin inhibit Antibiotic ADC Payload HBV Inhibitor AMP-activated protein kinase Hepatitis B virus Apoptosis Mitophagy Adriamycin Mitochondrial Autophagy Human immunodeficiency virus Autophagy ADC Cytotoxin inhibitor